Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1702 vs Wegovy in Chinese patients with obesity
NCT07036172Phase 3Recruiting
- Sponsor
- Huadong Medicine
- Start
- Jan 2025
- Primary completion
- Apr 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of HDM1702 in obesity, sponsored by Huadong Medicine. Started Jan 2025; status: recruiting.
02
Drugs
HDM1702
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07036172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07036172.